Sugi Predict

Sugi Predict / Compounds / SCHEMBL830265

SCHEMBL830265

SCHEMBL830265

COc1ccc2nc(Cl)cc(Cl)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ TP53 P04637 1/20 0.48
▸ KDM4E B2RXH2 7/20 0.48
▸ POLB P06746 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ SLC2A1 P11166 1/20 0.47
▸ BCHE P06276 4/20 0.47
▸ ACHE P22303 4/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ NQO2 P16083 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ GRIN1 Q05586 3/20 0.46
▸ GRIN2A Q12879 3/20 0.46
▸ HSP90AA1 P07900 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29420513 1.00 SMN1; SMN2 (0.48) SMN1; SMN2TP53KDM4EPOLBHSD17B10
SCHEMBL29420524 0.86 CYP1A2 (0.51) SMN1; SMN2KDM4EPOLBHSD17B10LMNA
SCHEMBL288844 0.86 CYP1A2 (0.51) SMN1; SMN2KDM4EPOLBHSD17B10LMNA
SCHEMBL2539829 0.84 KDM4E (0.60) SMN1; SMN2KDM4EPOLBHSD17B10LMNA
SCHEMBL2531203 0.84 POLB (0.62) SMN1; SMN2TP53KDM4EPOLBHSD17B10
SCHEMBL317463 0.84 LMNA (0.64) SMN1; SMN2TP53KDM4EPOLBHSD17B10
SCHEMBL23412192 0.83 NCF1 (0.56) SMN1; SMN2TP53KDM4EPOLBHSD17B10
SCHEMBL25912335 0.83 DHODH (0.48) SMN1; SMN2TP53KDM4EPOLBHSD17B10
Hydrochloric Acid SCHEMBL9732126 0.83 LMNA (0.62) SMN1; SMN2TP53KDM4EPOLBHSD17B10
SCHEMBL1289610 0.83 BCHE (0.51) KDM4EPOLBHSD17B10LMNASLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4617268-A1 QUINAZOLINE DERIVATIVES Kyoto University (JP) 2025-09-17 — — EP disclosed
US-12404249-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2025-09-02 — — US disclosed
EP-3802495-B1 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER C&C RES LAB (KR) 2025-07-02 — — EP disclosed
WO-2024101337-A1 QUINAZOLINE DERIVATIVES 国立大学法人京都大学 2024-05-16 — — WO disclosed
CN-112204010-B Heterocyclic derivatives and uses thereof C&C新药研究所 2024-03-19 — — CN disclosed
EP-3426248-B1 BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-11-15 — — EP disclosed
WO-2023125812-A1 SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF 上海海雁医药科技有限公司 2023-07-06 — — WO disclosed
WO-2023125812-A1 SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF 上海海雁医药科技有限公司 2023-07-06 — — WO disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 — — US disclosed
CN-108778273-B Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections 默沙东公司 2022-06-17 — — CN disclosed
EP-2061466-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS Xtl Biopharmaceuticals Ltd. (US) 2009-05-27 — — EP disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 — — US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 — — US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 — — US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 — — EP disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 — — WO disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 — — WO disclosed
US-20070060595-A1 Novel fused heterocyclic compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-03-15 — — US disclosed
EP-1671962-A1 NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-21 — — EP disclosed
WO-2002026713-A1 ANTIPARASITIC COMPOUNDS KING'S COLLEGE LONDON (GB) 2002-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060595-A1 Novel fused heterocyclic compound and use thereof JUN, CHUK, RELA SMN1; SMN2 4532/4885TP53 840/4885KDM4E 1873/4885
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A SMN1; SMN2 4686/4885TP53 335/4885KDM4E 1265/4885
US-12404249-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, IRF3 SMN1; SMN2 3885/4885TP53 15/4885KDM4E 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.